The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease. To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients.

Location: Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA
Principal Investigator: Shlomo Melmed, MD Cedars-Sinai Medical Center
Study Director: Ning-Ai Liu, MD, PhD Cedars-Sinai Medical Center

For more information, click here.